ReviewExperimental and therapeutic medicine2020
Glucagonoma: From skin lesions to the neuroendocrine component (Review).
Review in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.Endocrine oncology (Bristol, England) · 2025Article
- Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.International journal of molecular sciences · 2023Review
- Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.World journal of gastrointestinal surgery · 2022Review
- Primary hyperparathyroidism-related giant parathyroid adenoma (Review).Experimental and therapeutic medicine · 2022Review
- Growth Hormone and the Human Hair Follicle.International journal of molecular sciences · 2021Review
- Peutz-Jeghers syndrome: Skin manifestations and endocrine anomalies (Review).Experimental and therapeutic medicine · 2021Review
- Skin anomalies in acromegalic patients (Review of the practical aspects).Experimental and therapeutic medicine · 2021Review
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Current update on imaging for pancreatic neuroendocrine neoplasms.World journal of clinical oncology · 2021Review
- Anorexia nervosa: COVID-19 pandemic period (Review).Experimental and therapeutic medicine · 2021Review
- COVID-19-related thyroid conditions (Review).Experimental and therapeutic medicine · 2021Review
- Cutaneous Mastocytosis in Childhood-Update from the Literature.Journal of clinical medicine · 2021Review
- Glucagonoma of the pancreas: diagnostic approach and therapeutic algorithm for a rare nosological entity.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagonoma is a hormonally active rare pancreatic neuroendocrine tumour causing an excess of glucagon. This is a narrative review based on a multidisciplinary approach of the tumour. Typically associated dermatosis is necrolytic migratory erythema (NME) which is most frequently seen at disease onset. Insulin-dependent diabetes mellitus, depression, diarrhoea, deep vein thrombosis are also identified, as parts of so-called 'D' syndrome. Early diagnosis is life saving due to potential aggressive profile and high risk of liver metastasis. NME as paraneoplastic syndrome may be present for months and even years until adequate recognition and therapy; it is remitted after successful pancreatic surgery. Thus the level of practitioners' awareness is essential. If surgery is not curative, debulking techniques may improve the clinical aspects and even the outcome in association with other procedures such as embolization of hepatic metastasis; ablation of radiofrequency type; medical therapy including chemotherapy, targeted therapy with mTOR inhibitors such as everolimus, PRRT (peptide receptor radiotherapy), and somatostatin analogues (including combinations of medical treatments). Increased awareness of the condition involves multidisciplinary practitioners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.